Overexpression of HEXIM1 leads to limited availability of active P-TEFb as a result of sustained BET inhibition in myeloma cells having a significant impact on the transcription of a large number of genes, including oncogenic MYC [29]. This evidence concerns the gene HEXIM1 and plasma cell myeloma.